The UK’s National Institute for Health and Care Excellence (NICE) has recommended medtech giant Abbott’s heart failure sensor CardioMEMS.
This means that the CE-marked medical device will be available for routine use within the National Health Service (NHS) in adult patients with chronic heart failure. CardioMEMS is specifically recommended for those who have been previously hospitalised due to heart failure and are at continued risk.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The UK health watchdog’s recommendation of Abbott’s heart failure device falls in line with the government’s 10 Year Health Plan, which aims to use transformative technologies to reduce pressure on healthcare systems and shift the care paradigm to a more home-based model.
NICE is endorsing CardioMEMS based on positive data from three clinical trials, which found that the sensor system can reduce heart failure hospitalisations, emergency room visits and death by 34% in patients with Class II heart failure.
According to Carys Barton, chair of the British Society for Heart Failure, NICE’s guidance holds the “potential to diminish avoidable hospital visits,” while allowing physicians to make more timely and informed clinical decisions.
Director of the NICE healthtech programme, Anastasia Chalkidou, echoed this sentiment, adding that the CarioMEMS system offers a “real opportunity to improve care for patients living with chronic heart failure”.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“By enabling early detection of problems and timely medication adjustments, it has the potential to reduce emergency hospital admissions and help people manage their condition more effectively from the comfort of their own home,” Chalkidou said.
CardioMEMS is a wireless sensor implanted into the pulmonary artery that monitors a patient’s blood pressure and heart rate. Fitted via a minimally invasive procedure, the device is designed to provide healthcare professionals (HCPs) with remote readings, which allow them to act on early warning signals of cardiac exacerbations before symptoms escalate.
Heart failure market pumps up
The NICE’s call to recommend CardioMEMS is a positive step forward for Abbott, which saw strong growth from its medtech portfolio in FY2025 – triggering a YoY portfolio sales growth of 5.7%.
It also bolstered the company’s continued presence in the cardiovascular device market, which GlobalData forecasts will transition from a value of $72.6bn to $134.7bn between 2024 and 2034.
According to a UK-specific report from GlobalData, the cardiovascular monitoring devices market is set to reach a value of $378.5m in 2033.
Currently, Abbott is the third most successful company operating in the cardiovascular devices market according to FY2024 sales data, as the company brought in just under $770m through its cardiovascular portfolio during the year. The only companies to eclipse this value are Penumbra and Boston Scientific, which made $1.1bn and $1.7bn, respectively, from their marketed cardiovascular devices.
NICE currently also recommends Boston Scientific’s HeartLogic software, which works similarly to CardioMEMS by collating and sharing physiological data garnered from the company’s ICD and CRT-D devices with HCPs to help predict heart failure events.
